Pharmacogenomic considerations in the treatment of HIV infection

Surulivelrajan Mallayasamy; Scott R. Penzak

doi:10.1016/B978-0-12-812626-4.00008-5

Pharmacogenomic considerations in the treatment of HIV infection

Surulivelrajan Mallayasamy, Scott R. Penzak

Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Citations (Scopus)

Abstract

Potent combination antiretroviral therapy (cART) has reduced human immunodeficiency virus (HIV)-related morbidity and mortality, and transformed HIV infection into a chronic condition requiring lifelong antiretroviral (ARV) therapy. Ensuring the safety and efficacy of ARV therapy (ART), including optimizing treatment via pharmacogenetic testing, is now a reality. Human leukocyte antigen (HLA)-B*5701 testing for the abacavir hypersensitivity reaction has become the standard of care and represents a classic example of successful pharmacogenetic testing to improve ARV treatment. Efavirenz and atazanavir are two additional ARV medications for which pharmacogenetic testing of cytochrome P450 (CYP)2B6 and uridine diphosphate glucuronosyltransferase (UGT)1A1, respectively, has shown promise. Pharmacogenomics of HIV infection, including feasibility and cost analysis, is an important area for continued research.

Original language	English
Title of host publication	Pharmacogenomics
Subtitle of host publication	Challenges and Opportunities in Therapeutic Implementation
Publisher	Elsevier
Pages	227-245
Number of pages	19
ISBN (Electronic)	9780128126264
DOIs	https://doi.org/10.1016/B978-0-12-812626-4.00008-5
Publication status	Published - 01-01-2018

All Science Journal Classification (ASJC) codes

Medicine(all)
Pharmacology, Toxicology and Pharmaceutics(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-812626-4.00008-5

Cite this

@inbook{a065129aaf8c4b96814663d0bbc11b9c,

title = "Pharmacogenomic considerations in the treatment of HIV infection",

abstract = "Potent combination antiretroviral therapy (cART) has reduced human immunodeficiency virus (HIV)-related morbidity and mortality, and transformed HIV infection into a chronic condition requiring lifelong antiretroviral (ARV) therapy. Ensuring the safety and efficacy of ARV therapy (ART), including optimizing treatment via pharmacogenetic testing, is now a reality. Human leukocyte antigen (HLA)-B*5701 testing for the abacavir hypersensitivity reaction has become the standard of care and represents a classic example of successful pharmacogenetic testing to improve ARV treatment. Efavirenz and atazanavir are two additional ARV medications for which pharmacogenetic testing of cytochrome P450 (CYP)2B6 and uridine diphosphate glucuronosyltransferase (UGT)1A1, respectively, has shown promise. Pharmacogenomics of HIV infection, including feasibility and cost analysis, is an important area for continued research.",

author = "Surulivelrajan Mallayasamy and Penzak, {Scott R.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-812626-4.00008-5",

language = "English",

pages = "227--245",

booktitle = "Pharmacogenomics",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Pharmacogenomic considerations in the treatment of HIV infection

AU - Mallayasamy, Surulivelrajan

AU - Penzak, Scott R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Potent combination antiretroviral therapy (cART) has reduced human immunodeficiency virus (HIV)-related morbidity and mortality, and transformed HIV infection into a chronic condition requiring lifelong antiretroviral (ARV) therapy. Ensuring the safety and efficacy of ARV therapy (ART), including optimizing treatment via pharmacogenetic testing, is now a reality. Human leukocyte antigen (HLA)-B*5701 testing for the abacavir hypersensitivity reaction has become the standard of care and represents a classic example of successful pharmacogenetic testing to improve ARV treatment. Efavirenz and atazanavir are two additional ARV medications for which pharmacogenetic testing of cytochrome P450 (CYP)2B6 and uridine diphosphate glucuronosyltransferase (UGT)1A1, respectively, has shown promise. Pharmacogenomics of HIV infection, including feasibility and cost analysis, is an important area for continued research.

AB - Potent combination antiretroviral therapy (cART) has reduced human immunodeficiency virus (HIV)-related morbidity and mortality, and transformed HIV infection into a chronic condition requiring lifelong antiretroviral (ARV) therapy. Ensuring the safety and efficacy of ARV therapy (ART), including optimizing treatment via pharmacogenetic testing, is now a reality. Human leukocyte antigen (HLA)-B*5701 testing for the abacavir hypersensitivity reaction has become the standard of care and represents a classic example of successful pharmacogenetic testing to improve ARV treatment. Efavirenz and atazanavir are two additional ARV medications for which pharmacogenetic testing of cytochrome P450 (CYP)2B6 and uridine diphosphate glucuronosyltransferase (UGT)1A1, respectively, has shown promise. Pharmacogenomics of HIV infection, including feasibility and cost analysis, is an important area for continued research.

UR - http://www.scopus.com/inward/record.url?scp=85081122512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081122512&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-812626-4.00008-5

DO - 10.1016/B978-0-12-812626-4.00008-5

M3 - Chapter

AN - SCOPUS:85081122512

SP - 227

EP - 245

BT - Pharmacogenomics

PB - Elsevier

ER -

Pharmacogenomic considerations in the treatment of HIV infection

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this